Intragenic ERBB2 kinase mutations in tumours

Cited by (802)

Items 701–800 of 802

1. Human Epidermal Growth Factor (Her) in Gastric Cancer
   Jolanta Czyżewska · 2011 · InTech eBooks
2. Receptor Tyrosine Kinases
   David J. Matthews, Mary E. Gerritsen · 2010 · Wiley eBooks
3. Unveiling the Molecular Mechanisms Regulating the Activation of the ErbB Family Receptors at Atomic Resolution through Molecular Modeling and Simulations
   Andrew Shih · 2011 · ScholarlyCommons (University of Pennsylvania)
4. HER2 and TP53 in human breast cancer : Studies of methods and prognostic value
   Jenny Bergqvist · 2006 · Figshare
5. Que faire après l’apparition d’un échappement clinique au trastuzumab prescrit en première ligne métastatique ? Place du lapatinib et des nouveaux anti-HER2 Avec quelles associations ?
   J-M Ferrero, Jérôme Barrière · 2010 · Springer eBooks
6. New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material
   Juliana Eng, Alexander Edward Dela Cruz Drilon, Paul K. Paik · 2014 · Springer eBooks
7. Molecular Diagnosis of Lung Cancer
   Lucian R. Chirieac, Philip T. Cagle · 2012 · Molecular pathology library
8. Strategies in Patients with Other Molecular Alterations
   Manolo D’Arcangelo, Fred R. Hirsch · 2014 · Springer eBooks
9. Pathogenesis of Testicular Germ Cell Tumors from a Developmental Point of View
   Katharina Biermann · 2010 · RePub (Erasmus University Rotterdam)
10. Les mutations de HER2 dans les cancers bronchiques : caractéristiques et perspectives thérapeutiques
    Julien Mazières, Julie Milia · 2012 · Revue des Maladies Respiratoires Actualités
11. Drugs for Lung Cancer Treatment
    Young‐Chul Kim, Kyu Sik Kim · 2006 · Tuberculosis & respiratory diseases
12. Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies
    Juergen Barth, Christian Jackisch, Michael Untch · 2009 · Breast Care
13. RET and Other Genes: Therapeutic Targets In Lung Adenocarcinoma
    Takashi Kohno, Katsuya Tsuchihara, Hideaki Ogiwara, Hitoshi Ichikawa · 2014 · Lung Cancer Management
14. THE ROLE OF TYROSINE PHOSPHORYLATION IN THE FUNCTIONS OF THE TUMOR SUPPRESSOR GPRC5A
    Xiaofeng Lin · 2010 · Digital Commons-TMC (Texas Medical Center)
15. Thérapies ciblées : comment déterminer la cible ?
    M. Remmelink · 2014 · Revue des Maladies Respiratoires Actualités
16. Les nouveautés dans les carcinomes broncho-pulmonaires non à petites cellules
    Audrey Mansuet‐Lupo, Thierry Jo Molina, Diane Damotte · 2012 · Revue Francophone des Laboratoires
17. A molecular chink in the lung cancer armour
    Kwun Meng Fong, Rayleen Bowman · 2004 · Respirology
18. Driver mutations as predictive biomarkers in lung cancer
    Nicolas Girard · 2012 · Current Respiratory Care Reports
19. A correlational Bayesian network for DNA microarray data analysis
    Haiyan Piao · 2011 · International Conference on Biomedical Engineering and Informatics (BMEI)
20. TRANSPORT TRANSENDOTHÉLIAL DE GÈNES : ÉTUDES DYNAMIQUES DU PASSAGE SÉLECTIF DE POLYPLEXES AU TRAVERS DE L'ENDOTHÉLIUM VASCULAIRE PULMONAIRE.
    Eric Menneson · 2005 · HAL
21. The 2013 Incentive Award of the Okayama Medical Association in General Medical Science (2013 Yuuki Prize)
    Hiromasa Yamamoto · 2014 · Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
22. Functional analysis of mutant receptor tyrosine kinases involved in cancer pathogenesis
    Rama Krishna Kancha · 2010
23. The role of the NF-kappaB pathway in Her2-overexpressing breast cancer
    Evan Merkhofer · 2010
24. Targeting Drugs to Cancer: A Tough Journey to the Tumor Cell
    Shiran Ferber, Galia Tiram, Ronit Satchi‐Fainaro · 2013 · Springer eBooks
25. Nous mecanismes de resistència primària al trastuzumab (Herceptin): bases moleculars per a la determinació d'un nou subtipus de càncer de mama (Basal/ErbB2+)
    Cristina Oliveras‐Ferraros · 2013 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
26. HER
    Wolfgang J. Köstler, Yosef Yarden · 2013 · Cambridge University Press eBooks
27. Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine
    Peggy Ozenne · 2011
28. Les thérapeutiques ciblées ou le traitement des mécanismes moléculaires de la progression tumorale
    Jean‐Yves Blay, Jérôme Fayette, I. Ray-Coquard · 2006 · Springer eBooks
29. High-throughput analysis of kinase inhibitor drugs on cardiac function using engineered heart tissue constructs
    Genevieve Conant, Zhao Yimu, Milica Radisic · 2016 · Frontiers in Bioengineering and Biotechnology
30. Signal Transduction Inhibitors of the HER Family
    Christina E. Brzezniak, Corey Allan Carter, Anish Thomas, Giuseppe Giaccone · 2013 · CRC Press eBooks
31. Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer
    P. Ghosh, Yun Qiu, Ling‐Yu Wang, Hsing‐Jien Kung · 2013 · Cambridge University Press eBooks
32. her2 hyper-activation through the production of carboxy-terminal fragments
    Pier Davide Angelini · 2014 · TDX (Tesis Doctorals en Xarxa)
33. Principes van de medicamenteuze antikankerbehandeling
    Jacques De Grève, S. Van Belle, Stefan Sleijfer · 2011 · Bohn Stafleu van Loghum eBooks
34. Simple Sequence Mutations
    Christophe Béroud · 2016 · Springer eBooks
35. La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision
    Jacqueline Lehmann‐Che, Brigitte Poirot, Jean Christophe Boyer, Alexandre Evrard · 2017 · Therapies
36. Minor-Driver Mutant
    Akihiko Miyanaga · 2017 · Springer eBooks
37. Lung Adenocarcinoma
    Kathryn Finch Mileham, Jennifer Lynne Ersek, Edward S. Kim, Ignacio Ivan Wistuba · 2017 · Wiley eBooks
38. Identification and Validation of Driver Kinases from Next-Generation Sequencing Data
    Andri Leonidou, Barrie Peck, Rachael Natrajan · 2017 · Methods in molecular biology
39. Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2–Targeted Therapy
    Yakov Chudnovsky, Runjun D. Kumar, Alexa Betzig Schrock, Caitlin F. Connelly, Kyle A. Gowen, Garrett Michael Frampton, Rachel Erlich, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross et al. · 2017 · JCO Precision Oncology
40. Mutations as Predictive Biomarkers for Adenocarcinoma
    Navin R. Mahadevan, Lynette Marie Sholl · 2017 · Molecular pathology library
41. Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer
    Pilei Si, Ye Xu, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie · 2018 · Cancer Biomarkers
42. The human epidermal receptors in gastric cancer: molecular alterations and its role as therapeutic targets
    Andrea Rebeca Bustos-Carpinteyro, María Teresa Magaña‐Torres, Juan Ramón González-García, Juan Heriberto Torres-Jasso, Josefina Yoaly Sánchez-López · 2018 · Gaceta Médica de México
43. Unravelling Lung Cancer Heterogeneity and Associated Therapeutic Responses using in vivo and ex vivo Model Systems
    Ashwini Sakrepatna Nagaraj · 2018 · Työväentutkimus Vuosikirja
44. Targeting HER2 in Lung Cancer
    Ajaz Bulbul, Alessandro Leal, Hatim Husain · 2019 · Current cancer research
45. Targeting ErbB2 aberrations in non-small cell lung cancer
    Xuan Ge, Sara Tariq, Haiying Cheng, Balázs Halmos · 2019 · Precision Cancer Medicine
46. New Statistical Methods for Drawing Inference Based on High Dimensional Regression Models
    Zhe Fei · 2019 · Deep Blue (University of Michigan)
47. Understanding the response to EGFR targeting therapy in non-small-cell lung cancer using -omics approach
    Yan Zhou Tran · 2020 · Figshare
48. Identification of Novel Targets for Therapy in Solid Tumors
    Katherine E. Hutchinson · 2015
49. The Role of Nuclear Factor Kappa B in Myeloid Cells During Lung Carcinogenesis
    Allyson Gail Perry · 2016
50. Pathway-centric generalizable computational framework uncovers pathway markers governing chemoresistance across cancers
    Nusrat J Epsi · 2020
51. Paradigm shift in the management of metastatic Non-small Cell Lung Cancer
    Ruby Gupta, Melanie Smalley, Nwabundo Ifeyinwa Anusim, Vishal Jindal, Mandeep Singh Rahi, Sorab Gupta, Sachin Kumar Gupta, Ishmael A. Jaiyesimi · 2021
52. Integrative Analysis of Transcriptome and Methylation Data in Human Non-Small Cell Lung Cancer
    2021 · Scientific Research and Reviews
53. Sequence Mutations of Genes Pertaining to Malignancy in Cancer
    Nardnisa Sintupisut, Chen‐Hsiang Yeang · 2021 · Journal of Data Science
54. Modeling HER2 Mutations in Colorectal Cancer using a HER2 Transgenic Mouse Model and Gastrointestinal Organoids
    Elisa M. Murray · 2021 · Open Scholarship Institutional Repository (Washington University in St. Louis)
55. Lung Carcinoma
    Maria E. Arcila, Jason C. Chang, Laura J. Tafe · 2019 · Springer eBooks
56. Atezolizumab in the first-line treatment of metastatic non-small cell lung cancer. Clinical experience of the drug application. Case report
    Nikolai A. Ognerubov, Tatiana S. Antipova · 2022 · Journal of Modern Oncology
57. Paradigm shift in the management of metastatic Non-small Cell Lung Cancer
    Ruby Gupta, Melanie Smalley, Nwabundo Ifeyinwa Anusim, Vishal Jindal, Mandeep Singh Rahi, Sorab Gupta, Sachin Kumar Gupta, Ishmael A. Jaiyesimi · 2021
58. Poor efficacy of immune checkpoint inhibitors plus chemotherapy in the lung cancer patients with EGFR/ERBB2 exon 20 insertion
    Yang Fu, Yue Zheng, Yueyun Chen, Peipei Wang, Qing Li, Ting Liu, Zhenyu Ding · 2022 · Research Square
59. “Stats 101” Revision
    David I. Warton · 2021 · Methods in statistical ecology
60. Understanding the Molecular Kinetics in NSCLC Through Computational Method
    Prajakta Nimsarkar, Pooja Gulhane, Shailza Singh · 2022 · Springer eBooks
61. Cancer Genomics and Evolution
    William P.D. Hendricks, Aleksandar Sekulić, Alan Haruo Bryce, Muhammed Murtaza, Pilar Ramos, Jessica D. Lang, Timothy G. Whitsett, Timothy K. McDaniel, Russell C. Rockne, Nicholas E. Banovich et al. · 2022 · Wiley eBooks
62. Genetic and Epigenetic Dysregulation in Environmental Disease
    Kenneth S. Ramos, Abeer A. I. Hassanin, Yingshan Wang · 2023 · Elsevier eBooks
63. Somatic mutation: Pharmacogenomics in oncology care
    Satyabrata Kundu, Shriyansh Srivastava, Shamsher Singh · 2024 · Elsevier eBooks
64. Additional file 1 of Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases
    Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Kaiyan Chen, Yun Fan · 2021 · Figshare
65. [Research Progress of Antibody-conjugated Drugs in Non-small Cell Lung Cancer].
    Yunbo Liu, Sen Wei · 2024 · PubMed Central
66. Targeted radionuclide therapy: current status and prospects
    Vladimir Vodeneev, Andrei V. Zvyagin, Natalia Y. Shilyagina, Д. А. Куликов, А. В. Куликов, Sergey V. Gudkov · 2015 · Genes and Cells
67. 20 Pathology of Metastatic Spinal and Vertebral Column Neoplasms
    2025 · Thieme Medical Publishers eBooks
68. Thermodynamics and mechanism of afatinib–EGFR binding through a QM/MM approach
    Anjali Kisku, Raghav Wahi, Raj Kumar Mishra · 2025 · RSC Medicinal Chemistry
69. Machine Learning-Based Detection of EGFR Mutation and HER2 Overexpression in Metastatic Brain Adenocarcinoma: Systematic Review and Meta-Analysis
    Mohammad Sadra Gholami Chahkand, Mohammad Amin Karimi, Komeil Aghazadeh-Habashi, Fatemeh Esmaeilpour Moallem, Rozhin Mehrabanpour, Parisa Alsadat Dadkhah, Roja Esmailinia, Negin Esfandiari, Eftekhar Azarm, Seyyed Kiarash Sadat Rafiei et al. · 2025 · Topics in Magnetic Resonance Imaging
70. Screening on Lung Cancer: Etiology, Pathophysiology, Treatment
    Warkhade Kishor K, Reshma Dilip Pawar · 2025 · International Journal of Advanced Research in Science Communication and Technology
71. Harmonizing the DESTINY and Broadening the HORIZON of HER2 ADCs in the Face of Next-Generation HER2 TKI for the Treatment Options of HER2 mutations positive (HER2+) NSCLC
    Yu Xu, Misako Nagasaka, Sai‐Hong Ignatius Ou, Mengxia Li · 2025 · Journal of Thoracic Oncology
72. Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a case report
    Zhenyu Ke, Hongbo Yang, Meng Xing, Shasha Bi, Fujun Yang · 2025 · Frontiers in Oncology
73. Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy
    Moulay A. Alaoui‐Jamali, Devanand M. Pinto · 2007 · Humana Press eBooks
74. Affinity protein based inhibition of cancer related signaling pathways
    Erik Vernet · 2009 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
75. Additional file 3 of Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases
    Xu, Yanjun, Huang, Zhiyu, Yu, Xiaoqing, Chen, Kaiyan, Fan, Yun · 2021 · Figshare
76. Additional file 2 of Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases
    Xu, Yanjun, Huang, Zhiyu, Yu, Xiaoqing, Chen, Kaiyan, Fan, Yun · 2021 · Figshare
77. Additional file 1 of MR-based radiomics predictive modelling of EGFR mutation and HER2 overexpression in metastatic brain adenocarcinoma: a two-centre study
    Li, Yanran, Jin, Yong, Yunling Wang, Liu, Wenya, Wenxiao Jia, Wang, Jian · 2024 · Figshare
78. Additional file 2 of MR-based radiomics predictive modelling of EGFR mutation and HER2 overexpression in metastatic brain adenocarcinoma: a two-centre study
    Li, Yanran, Jin, Yong, Yunling Wang, Liu, Wenya, Wenxiao Jia, Jian Wang · 2024 · Figshare
79. The GigaAssay: A combined high throughput and highly accurate platform for variant classification
    Christopher J. Giacoletto, Liz J. Valente, Lancer Brown, Sara E. Patterson, Rewatee H. Gokhale, Susan M. Mockus, Wayne W. Grody, Hong‐Wen Deng, Jerome I. Rotter, Martin R. Schiller · 2025 · New Biotechnology
80. Exome Sequencing Identifies Variants in MLH1 and ERBB2 as Potential Cancer‐Predisposing Factors in Familial Early‐Onset Colorectal Cancer
    Behnaz Bagheri, Neda Mohsen-Pour, Najmeh Salehi, Pardis Ketabi Moghadam, Adel Zeinalpour, Amir Sadeghi, Samira Kalayinia, Nayeralsadat Fatemi · 2026 · The Kaohsiung Journal of Medical Sciences
81. Role of the diaphanous-related formins DRF1, DRF2 and DRF3 in ErbB2-dependent cell motility and microtubule dynamics
    Pascale Daou · 2013 · theses.fr (ABES)
82. Régulation de l'invasion cellulaire induite par les tyrosine kinases dans le cancer du sein
    Clément Chevalier · 2014 · theses.fr (ABES)
83. Implication de Nanos-3 dans l’invasion tumorale broncho-pulmonaire
    Simon Grelet · 2014 · theses.fr (ABES)
84. Contrôle de la progression tumorale broncho-pulmonaire par FHIT : Implication du récepteur HER2
    Amina Jouida · 2017 · theses.fr (ABES)
85. Clinical Efficacy of HER2-targeted Monotherapy in ERBB2-mutant Non–Small-Cell Lung Cancer: A Systematic Review and Single-arm Meta-Analysis
    Fumihiro Kashizaki, Ryusuke Orii, Shohei Watanabe, Kentaro Yumoto · 2026 · Clinical Lung Cancer
86. Compréhension des étapes précoces de la résistance adaptative aux inhibiteurs de tyrosine kinase de l'EGFR dans les cancers bronchiques
    Sarah Figarol · 2020 · theses.fr (ABES)
87. Une nouvelle stratégie thérapeutique pour prolonger la réponse du cancer bronchique aux inhibiteurs d’EGFR en prévenant l’émergence des cellules résistantes
    Lisa Brunet · 2021 · theses.fr (ABES)
88. EGFR ’s Poor Sibling
    David Paul Carbone · 2026 · New England Journal of Medicine
89. HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power
    Vivek Subbiah, Martin Dietrich, Xiuning Le · 2026 · Targeted Oncology
90. Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation
    Miao Chen, Jinal Gandhib, Shuyan Wu, Haiying Cheng · 2026 · Expert Opinion on Pharmacotherapy
91. ProphDR: An Interpretable Deep Learning Model for Predicting Cancer Drug Response via Multi-Omics and Cross-Attention Mechanisms
    Yundian Zeng, Qing Ye, Jike Wang, Odin Zhang, Hongyan Du, Zhenxing Wu, Dejun Jiang, Peichen Pan, Yu Kang, Jiming Chen et al. · 2026 · Journal of Chemical Information and Modeling
92. Exploring the Continuum of HER2 TKD Mutations and HER2 “Sensitizing Mutations” in NSCLC and Retiring the Term “HER2 Exon 20 Insertions”
    Xiaosong Li, Kang Qi, Sai‐Hong Ignatius Ou, Yanyan Hu · 2026 · Journal of Thoracic Oncology
93. Matched Analogue Analysis of Structural Responses Before and After Covalent Bond Formation in Wild-Type and A775_G776insYVMA HER2
    Keke Fan, Yanan Xu, Qiwei Ye, Mingliang Zeng, Hongwang Xiao, Shanyan Mo, Sha Hu, Liming Hu · 2026 · International Journal of Molecular Sciences
94. Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort
    Masahiro Yamashita, Kiichiro Ninomiya, Shuta Tomida, Eiji Nakata, Ayako Morita, Naofumi Hara, Kenji Takada, Go Makimoto, Toshio Kubo, Eiki Ichihara et al. · 2026 · European Journal of Cancer
95. DYT8 drives lung adenocarcinoma through EGFR-mediated PSMC6 recruitment and uncharacterized phosphorylation at Ser 306 and 525 of c-Src.
    Mei-Lian Cai, Meng-Yan Wang, Xiao-Jun Zhao, Yan Xing, Han-Ze Liu, Rong-Guang Shao, Ming-Hua Chen, Wu-Li Zhao · 2026 · Acta Pharmacologica Sinica
96. BindingDB Entry 50022551: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
    BindingDB · 2025 · UC San Diego
97. BindingDB Entry 50022616: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
    BindingDB · 2025 · UC San Diego
98. BindingDB Entry 5651: Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
    BindingDB · 2012 · UC San Diego
99. BindingDB Entry 50022481: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
    BindingDB · 2025 · UC San Diego
100. Somatic Mutations in Breast Cancer Genomes : Discovery and Validation of Breast Cancer Genes
     Xiang Jiao · 2012 · Uppsala University Publications (Uppsala University)